{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:38:20Z","timestamp":1776919100560,"version":"3.51.2"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10335-0","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:59:50Z","timestamp":1776916790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving therapeutics in colorectal cancer peritoneal metastases"],"prefix":"10.1007","volume":"45","author":[{"given":"Justin M.","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt S.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwasi Ansere","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"10335_CR1","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/cancers16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel, G., Ghasemi-Kebria, F., & Malekzadeh, R. (2024). Colorectal cancer: Epidemiology, risk factors, and prevention. Cancers, 16, 1530.","journal-title":"Cancers"},{"key":"10335_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan, E., et al. (2023). Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut, 72, 338\u2013344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"key":"10335_CR3","doi-asserted-by":"publisher","first-page":"E499","DOI":"10.15167\/2421-4248\/jpmh2024.65.4.3071","volume":"65","author":"D Darmadi","year":"2024","unstructured":"Darmadi, D., Mohammadian-Hafshejani, A., & Kheiri, S. (2024). Global disparities in colorectal cancer: Unveiling the present landscape of incidence and mortality rates, analyzing geographical variances, and assessing the human development index. Journal of Preventive Medicine and Hygiene, 65, E499-e514. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2024.65.4.3071","journal-title":"Journal of Preventive Medicine and Hygiene"},{"key":"10335_CR4","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) Cancer statistics, 2025. CA: A Cancer Journal for Clinicians 75, 10\u201345, https:\/\/doi.org\/10.3322\/caac.21871","DOI":"10.3322\/caac.21871"},{"key":"10335_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17363-0","author":"KS Schultz","year":"2025","unstructured":"Schultz, K. S., et al. (2025). Consensus guideline for the management of colorectal cancer with peritoneal metastases. Annals of Surgical Oncology. https:\/\/doi.org\/10.1245\/s10434-025-17363-0","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko, J., et al. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17, 1709\u20131719. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9","journal-title":"The Lancet Oncology"},{"key":"10335_CR7","doi-asserted-by":"publisher","first-page":"650098","DOI":"10.3389\/fonc.2021.650098","volume":"11","author":"O Kranenburg","year":"2021","unstructured":"Kranenburg, O., van der Speeten, K., & de Hingh, I. (2021). Peritoneal metastases from colorectal cancer: Defining and addressing the challenges. Frontiers in Oncology, 11, 650098. https:\/\/doi.org\/10.3389\/fonc.2021.650098","journal-title":"Frontiers in Oncology"},{"key":"10335_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jso.23878","volume":"111","author":"MR Torkzad","year":"2015","unstructured":"Torkzad, M. R., et al. (2015). Comparison between MRI and CT in prediction of peritoneal Carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist. Journal of Surgical Oncology, 111, 746\u2013751. https:\/\/doi.org\/10.1002\/jso.23878","journal-title":"Journal of Surgical Oncology"},{"key":"10335_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9, D., et al. (2013). Is there a possibility of a cure in patients with colorectal peritoneal Carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Annals of Surgery, 257, 1065\u20131071. https:\/\/doi.org\/10.1097\/SLA.0b013e31827e9289","journal-title":"Annals of Surgery"},{"key":"10335_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne, D. G., Fook, S., Loi, C., & Seow-Choen, F. (2002). Peritoneal Carcinomatosis from colorectal cancer. British Journal of Surgery, 89, 1545\u20131550. https:\/\/doi.org\/10.1046\/j.1365-2168.2002.02274.x","journal-title":"British Journal of Surgery"},{"key":"10335_CR11","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko, J., et al. (2010). Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal Carcinomatosis. Cancer, 116, 3756\u20133762. https:\/\/doi.org\/10.1002\/cncr.25116","journal-title":"Cancer"},{"key":"10335_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","volume":"243","author":"MJ Koppe","year":"2006","unstructured":"Koppe, M. J., Boerman, O. C., Oyen, W. J., & Bleichrodt, R. P. (2006). Peritoneal Carcinomatosis of colorectal origin: Incidence and current treatment strategies. Annals of Surgery, 243, 212\u2013222. https:\/\/doi.org\/10.1097\/01.sla.0000197702.46394.16","journal-title":"Annals of Surgery"},{"key":"10335_CR13","doi-asserted-by":"publisher","first-page":"20180102","DOI":"10.1515\/pp-2018-0102","volume":"3","author":"J Franko","year":"2018","unstructured":"Franko, J. (2018). Therapeutic efficacy of systemic therapy for colorectal peritoneal Carcinomatosis: Surgeon\u2019s perspective. Pleura Peritoneum, 3, 20180102. https:\/\/doi.org\/10.1515\/pp-2018-0102","journal-title":"Pleura Peritoneum"},{"key":"10335_CR14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ejso.2005.06.002","volume":"31","author":"AL Bloemendaal","year":"2005","unstructured":"Bloemendaal, A. L., Verwaal, V. J., van Ruth, S., Boot, H., & Zoetmulder, F. A. (2005). Conventional surgery and systemic chemotherapy for peritoneal Carcinomatosis of colorectal origin: A prospective study. European Journal of Surgical Oncology, 31, 1145\u20131151. https:\/\/doi.org\/10.1016\/j.ejso.2005.06.002","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v","volume":"63","author":"DZ Chu","year":"1989","unstructured":"Chu, D. Z., Lang, N. P., Thompson, C., Osteen, P. K., & Westbrook, K. C. (1989). Peritoneal Carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer, 63, 364\u2013367. https:\/\/doi.org\/10.1002\/1097-0142(19890115)63:2%3c364::aid-cncr2820630228%3e3.0.co;2-v","journal-title":"Cancer"},{"key":"10335_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3393\/ac.2021.00920.0131","volume":"37","author":"YJ Kim","year":"2021","unstructured":"Kim, Y. J., & Kim, C. H. (2021). Treatment for peritoneal metastasis of patients with colorectal cancer. Ann Coloproctol, 37, 425\u2013433. https:\/\/doi.org\/10.3393\/ac.2021.00920.0131","journal-title":"Ann Coloproctol"},{"key":"10335_CR17","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3747\/co.22.2058","volume":"22","author":"P Dub\u00e9","year":"2015","unstructured":"Dub\u00e9, P., et al. (2015). Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Current Oncology, 22, e100-112. https:\/\/doi.org\/10.3747\/co.22.2058","journal-title":"Current Oncology"},{"key":"10335_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s13193-016-0498-0","volume":"7","author":"SJ Valle","year":"2016","unstructured":"Valle, S. J., et al. (2016). Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian Journal of Surgical Oncology, 7, 152\u2013159. https:\/\/doi.org\/10.1007\/s13193-016-0498-0","journal-title":"Indian Journal of Surgical Oncology"},{"key":"10335_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","volume":"12","author":"VJ Verwaal","year":"2005","unstructured":"Verwaal, V. J., et al. (2005). Long-term survival of peritoneal Carcinomatosis of colorectal origin. Annals of Surgical Oncology, 12, 65\u201371. https:\/\/doi.org\/10.1007\/s10434-004-1167-z","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net, F., et al. (2021). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. The lancet Oncology, 22, 256\u2013266. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4","journal-title":"The lancet Oncology"},{"key":"10335_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.22.02644","volume":"42","author":"ES Zwanenburg","year":"2023","unstructured":"Zwanenburg, E. S., et al. (2023). Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): 5-year results of a randomized multicenter trial. Journal of Clinical Oncology, 42, 140\u2013145. https:\/\/doi.org\/10.1200\/JCO.22.02644","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR22","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1245\/s10434-023-13292-y","volume":"30","author":"C Bakkers","year":"2023","unstructured":"Bakkers, C., Rovers, K. P., Rijken, A., Nienhuijs, S. W., & de Hingh, I. (2023). ASO author reflections: Patient-reported outcomes of the CAIRO6 phase II trial. Annals of Surgical Oncology, 30, 2689\u20132690. https:\/\/doi.org\/10.1245\/s10434-023-13292-y","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.21037\/jgo.2019.12.10","volume":"11","author":"G Tan","year":"2020","unstructured":"Tan, G., & Wong, J. (2020). Surgical management and hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer. J Gastrointest Oncol, 11, 508\u2013512. https:\/\/doi.org\/10.21037\/jgo.2019.12.10","journal-title":"J Gastrointest Oncol"},{"key":"10335_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2022","unstructured":"Morris, V. K., et al. (2022). Treatment of metastatic colorectal cancer: ASCO guideline. Journal of Clinical Oncology, 41, 678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","volume":"31","author":"M H\u00fcbner","year":"2024","unstructured":"H\u00fcbner, M., et al. (2024). 2022 Peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: Colorectal cancer. Annals of Surgical Oncology, 31, 567\u2013576. https:\/\/doi.org\/10.1245\/s10434-023-14368-5","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR26","unstructured":"(2025) NCCN Guidelines Version 4.2025 Colon Cancer., https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf"},{"key":"10335_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A., et al. (2023). Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34, 10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","journal-title":"Annals of Oncology"},{"issue":"12","key":"10335_CR28","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1007\/s10147-025-02899-8","volume":"30","author":"Y Kinugasa","year":"2025","unstructured":"Kinugasa, Y., Uehara, K., Yamaguchi, K., et al. (2025). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 30(12), 2410\u20132463. https:\/\/doi.org\/10.1007\/s10147-025-02899-8","journal-title":"International Journal of Clinical Oncology"},{"key":"10335_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/dcr.0000000000000412","volume":"58","author":"P Quere","year":"2015","unstructured":"Quere, P., et al. (2015). Epidemiology, management, and survival of peritoneal Carcinomatosis from colorectal cancer: A population-based study. Diseases of the Colon and Rectum, 58, 743\u2013752. https:\/\/doi.org\/10.1097\/dcr.0000000000000412","journal-title":"Diseases of the Colon and Rectum"},{"key":"10335_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","volume":"16","author":"JL Koh","year":"2009","unstructured":"Koh, J. L., Yan, T. D., Glenn, D., & Morris, D. L. (2009). Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal Carcinomatosis. Annals of Surgical Oncology, 16, 327\u2013333. https:\/\/doi.org\/10.1245\/s10434-008-0234-2","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","volume":"14","author":"J Esquivel","year":"2007","unstructured":"Esquivel, J., et al. (2007). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of surgical oncology. Annals of Surgical Oncology, 14, 128\u2013133. https:\/\/doi.org\/10.1245\/s10434-006-9185-7","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR32","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/1097-0142(19930901)72:5<1631::aid-cncr2820720523>3.0.co;2-i","volume":"72","author":"P Jacquet","year":"1993","unstructured":"Jacquet, P., Jelinek, J. S., Steves, M. A., & Sugarbaker, P. H. (1993). Evaluation of computed tomography in patients with peritoneal Carcinomatosis. Cancer, 72, 1631\u20131636. https:\/\/doi.org\/10.1002\/1097-0142(19930901)72:5%3c1631::aid-cncr2820720523%3e3.0.co;2-i","journal-title":"Cancer"},{"key":"10335_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00261-008-9372-z","volume":"34","author":"T Franiel","year":"2009","unstructured":"Franiel, T., et al. (2009). Multi-detector CT in peritoneal Carcinomatosis: Diagnostic role of thin slices and multiplanar reconstructions. Abdominal Imaging, 34, 49\u201354. https:\/\/doi.org\/10.1007\/s00261-008-9372-z","journal-title":"Abdominal Imaging"},{"key":"10335_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi, B., et al. (2000). Peritoneal Carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358\u2013363. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o","journal-title":"Cancer"},{"key":"10335_CR35","doi-asserted-by":"publisher","unstructured":"Chia, C. S. et al. (2022) Prospective Comparison of the Performance of MRI Versus CT in the Detection and Evaluation of Peritoneal Surface Malignancies. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14133179","DOI":"10.3390\/cancers14133179"},{"key":"10335_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.suronc.2020.02.010","volume":"33","author":"M Leimk\u00fchler","year":"2020","unstructured":"Leimk\u00fchler, M., et al. (2020). Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: A retrospective cohort study. Surgical Oncology, 33, 135\u2013140. https:\/\/doi.org\/10.1016\/j.suronc.2020.02.010","journal-title":"Surgical Oncology"},{"key":"10335_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman, J., et al. (2012). Incidence, prevalence and risk factors for peritoneal Carcinomatosis from colorectal cancer. British Journal of Surgery, 99, 699\u2013705. https:\/\/doi.org\/10.1002\/bjs.8679","journal-title":"British Journal of Surgery"},{"key":"10335_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YR van Gestel","year":"2014","unstructured":"van Gestel, Y. R., et al. (2014). Metachronous peritoneal Carcinomatosis after curative treatment of colorectal cancer. European Journal of Surgical Oncology, 40, 963\u2013969. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/s1470-2045(17)30336-4","volume":"18","author":"J Tseng","year":"2017","unstructured":"Tseng, J., et al. (2017). Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. The lancet Oncology, 18, 711\u2013712. https:\/\/doi.org\/10.1016\/s1470-2045(17)30336-4","journal-title":"The lancet Oncology"},{"key":"10335_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen, N., van de Velde, C. J. H., de Wilt, J. H. W., & Nagtegaal, I. D. (2014). Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Annals of Oncology, 25, 651\u2013657. https:\/\/doi.org\/10.1093\/annonc\/mdt591","journal-title":"Annals of Oncology"},{"key":"10335_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2005.09.016","volume":"32","author":"E de Bree","year":"2006","unstructured":"de Bree, E., et al. (2006). Preoperative computed tomography and selection of patients with colorectal peritoneal Carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology, 32, 65\u201371. https:\/\/doi.org\/10.1016\/j.ejso.2005.09.016","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jso.20049","volume":"86","author":"E de Bree","year":"2004","unstructured":"de Bree, E., et al. (2004). Peritoneal Carcinomatosis from colorectal or appendiceal origin: Correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. Journal of Surgical Oncology, 86, 64\u201373. https:\/\/doi.org\/10.1002\/jso.20049","journal-title":"Journal of Surgical Oncology"},{"key":"10335_CR43","doi-asserted-by":"publisher","unstructured":"Reginelli, A. et al. (2023). Peritoneal carcinosis: What the radiologist needs to know. Diagnostics (Basel) 13. https:\/\/doi.org\/10.3390\/diagnostics13111974","DOI":"10.3390\/diagnostics13111974"},{"key":"10335_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","volume":"47","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer, M. E., et al. (2020). PET\/MRI versus PET\/CT in oncology: A prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. European Journal of Nuclear Medicine and Molecular Imaging, 47, 51\u201360. https:\/\/doi.org\/10.1007\/s00259-019-04452-y","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10335_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3348\/kjr.2023.0840","volume":"25","author":"C Fu","year":"2024","unstructured":"Fu, C., Zhang, B., Guo, T., & Li, J. (2024). Imaging evaluation of peritoneal metastasis: Current and promising techniques. Korean Journal of Radiology, 25, 86\u2013102. https:\/\/doi.org\/10.3348\/kjr.2023.0840","journal-title":"Korean Journal of Radiology"},{"key":"10335_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/jso.27979","volume":"130","author":"D Caruso","year":"2024","unstructured":"Caruso, D., et al. (2024). Imaging of peritoneal surface malignancies. Journal of Surgical Oncology, 130, 1203\u20131212. https:\/\/doi.org\/10.1002\/jso.27979","journal-title":"Journal of Surgical Oncology"},{"key":"10335_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40644-025-00887-9","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., et al. (2025). Characteristics of (18)F-FAPI-04 PET\/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with (18)F-FDG PET\/CT. Cancer Imaging, 25, 66. https:\/\/doi.org\/10.1186\/s40644-025-00887-9","journal-title":"Cancer Imaging"},{"key":"10335_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.suronc.2017.03.002","volume":"26","author":"M Gutowski","year":"2017","unstructured":"Gutowski, M., et al. (2017). SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. Surgical Oncology, 26, 153\u2013162. https:\/\/doi.org\/10.1016\/j.suronc.2017.03.002","journal-title":"Surgical Oncology"},{"key":"10335_CR49","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1245\/s10434-024-15165-4","volume":"31","author":"P Wagner","year":"2024","unstructured":"Wagner, P., et al. (2024). Detection of residual peritoneal metastases following cytoreductive surgery using pegsitacianine, a pH-sensitive imaging agent: Final results from a phase II study. Annals of Surgical Oncology, 31, 4726\u20134734. https:\/\/doi.org\/10.1245\/s10434-024-15165-4","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/XCS.0000000000001076","author":"K Schultz","year":"2024","unstructured":"Schultz, K., & Mongiu, A. (2024). NESS Commentary re Shergill 2023\u20131231. Journal of the American College of Surgeons. https:\/\/doi.org\/10.1097\/XCS.0000000000001076","journal-title":"Journal of the American College of Surgeons"},{"key":"10335_CR51","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/xcs.0000000000001028","volume":"238","author":"VV Bansal","year":"2024","unstructured":"Bansal, V. V., et al. (2024). Utility of circulating tumor DNA assessment in characterizing recurrence sites after optimal resection for metastatic colorectal cancer. Journal of the American College of Surgeons, 238, 1013\u20131020. https:\/\/doi.org\/10.1097\/xcs.0000000000001028","journal-title":"Journal of the American College of Surgeons"},{"key":"10335_CR52","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/jco.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022). Using circulating tumor DNA in colorectal cancer: Current and evolving practices. Journal of Clinical Oncology, 40, 2846\u20132857. https:\/\/doi.org\/10.1200\/jco.21.02615","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR53","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1078-0432.Ccr-20-3677","volume":"27","author":"Y Kagawa","year":"2021","unstructured":"Kagawa, Y., et al. (2021). Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: The METABEAM study. Clinical Cancer Research, 27, 2515\u20132522. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3677","journal-title":"Clinical Cancer Research"},{"key":"10335_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"30","author":"BG Sullivan","year":"2023","unstructured":"Sullivan, B. G., et al. (2023). Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Annals of Surgical Oncology, 30, 278\u2013284. https:\/\/doi.org\/10.1245\/s10434-022-12399-y","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits, C., & Clarke, S. (2012). Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clinical Pharmacokinetics, 51, 203\u2013224. https:\/\/doi.org\/10.2165\/11598890-000000000-00000","journal-title":"Clinical Pharmacokinetics"},{"key":"10335_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A., Church, M., Rothwell, D., Dive, C., & Cook, N. (2022). Circulating tumour DNA - looking beyond the blood. Nature Reviews. Clinical Oncology, 19, 600\u2013612. https:\/\/doi.org\/10.1038\/s41571-022-00660-y","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10335_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12029-023-00959-8","volume":"55","author":"JM Baumgartner","year":"2024","unstructured":"Baumgartner, J. M., & Botta, G. P. (2024). Role of circulating tumor DNA among patients with colorectal peritoneal metastases. Journal of Gastrointestinal Cancer, 55, 41\u201346. https:\/\/doi.org\/10.1007\/s12029-023-00959-8","journal-title":"Journal of Gastrointestinal Cancer"},{"issue":"6","key":"10335_CR58","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/jcm9061738","volume":"9","author":"JJ Beagan","year":"2020","unstructured":"Beagan, J. J., et al. (2020). Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: A clinical feasibility study. Journal of Clinical Medicine, 9(6), 1738. https:\/\/doi.org\/10.3390\/jcm9061738","journal-title":"Journal of Clinical Medicine"},{"key":"10335_CR59","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/sla.0000000000005856","volume":"278","author":"A Dhiman","year":"2023","unstructured":"Dhiman, A., et al. (2023). Role of tumor-informed personalized circulating tumor DNA assay in informing recurrence in patients with peritoneal metastases from colorectal and high-grade appendix cancer undergoing curative-intent surgery. Annals of Surgery, 278, 925\u2013931. https:\/\/doi.org\/10.1097\/sla.0000000000005856","journal-title":"Annals of Surgery"},{"key":"10335_CR60","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","volume":"25","author":"JM Baumgartner","year":"2018","unstructured":"Baumgartner, J. M., et al. (2018). Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Annals of Surgical Oncology, 25, 2400\u20132408. https:\/\/doi.org\/10.1245\/s10434-018-6561-z","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR61","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1245\/s10434-020-08331-x","volume":"27","author":"JM Baumgartner","year":"2020","unstructured":"Baumgartner, J. M., et al. (2020). Prognostic utility of pre- and postoperative circulating tumor DNA liquid biopsies in patients with peritoneal metastases. Annals of Surgical Oncology, 27, 3259\u20133267. https:\/\/doi.org\/10.1245\/s10434-020-08331-x","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR62","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.Mct-16-0436","volume":"16","author":"H Husain","year":"2017","unstructured":"Husain, H., et al. (2017). Cell-free DNA from ascites and pleural effusions: Molecular insights into genomic aberrations and disease biology. Molecular Cancer Therapeutics, 16, 948\u2013955. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0436","journal-title":"Molecular Cancer Therapeutics"},{"key":"10335_CR63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1245\/s10434-015-4627-8","volume":"23","author":"M Faron","year":"2016","unstructured":"Faron, M., et al. (2016). Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Annals of Surgical Oncology, 23, 114\u2013119. https:\/\/doi.org\/10.1245\/s10434-015-4627-8","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR64","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","volume":"22","author":"D Go\u00e9r\u00e9","year":"2015","unstructured":"Go\u00e9r\u00e9, D., et al. (2015). Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Annals of Surgical Oncology, 22, 2958\u20132964. https:\/\/doi.org\/10.1245\/s10434-015-4387-5","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR65","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","volume":"40","author":"D Elias","year":"2014","unstructured":"Elias, D., et al. (2014). Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. European Journal of Surgical Oncology, 40, 1467\u20131473. https:\/\/doi.org\/10.1016\/j.ejso.2014.06.006","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR66","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.ejso.2020.07.039","volume":"46","author":"H Birgisson","year":"2020","unstructured":"Birgisson, H., et al. (2020). Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology, 46, 2283\u20132291. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.039","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR67","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/codi.15003","volume":"22","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan, V., et al. (2020). Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: A systematic review and meta-analysis. Colorectal Disease, 22, 1482\u20131495. https:\/\/doi.org\/10.1111\/codi.15003","journal-title":"Colorectal Disease"},{"key":"10335_CR68","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/sla.0000000000001593","volume":"263","author":"R Kwakman","year":"2016","unstructured":"Kwakman, R., et al. (2016). Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: A meta-analysis. Annals of Surgery, 263, 1102\u20131111. https:\/\/doi.org\/10.1097\/sla.0000000000001593","journal-title":"Annals of Surgery"},{"key":"10335_CR69","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1245\/s10434-014-4111-x","volume":"22","author":"PM Polanco","year":"2015","unstructured":"Polanco, P. M., et al. (2015). Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Annals of Surgical Oncology, 22, 1673\u20131679. https:\/\/doi.org\/10.1245\/s10434-014-4111-x","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR70","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/bjs.9674","volume":"101","author":"S Kusamura","year":"2014","unstructured":"Kusamura, S., et al. (2014). Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. British Journal of Surgery, 101, 1758\u20131765. https:\/\/doi.org\/10.1002\/bjs.9674","journal-title":"British Journal of Surgery"},{"key":"10335_CR71","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1245\/s10434-024-15945-y","volume":"31","author":"Y Ciftci","year":"2024","unstructured":"Ciftci, Y., Radomski, S. N., Johnson, B. A., Johnston, F. M., & Greer, J. B. (2024). Triphasic learning curve of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Annals of Surgical Oncology, 31, 7987\u20137997. https:\/\/doi.org\/10.1245\/s10434-024-15945-y","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3978\/j.issn.2078-6891.2015.099","volume":"7","author":"R Rajeev","year":"2016","unstructured":"Rajeev, R., Klooster, B., & Turaga, K. K. (2016). Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol, 7, 122\u2013128. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.099","journal-title":"J Gastrointest Oncol"},{"key":"10335_CR73","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1245\/s10434-020-08781-3","volume":"27","author":"D Schuitevoerder","year":"2020","unstructured":"Schuitevoerder, D., Sherman, S. K., Izquierdo, F. J., Eng, O. S., & Turaga, K. K. (2020). Assessment of the surgical workforce pertaining to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the United States. Annals of Surgical Oncology, 27, 3097\u20133102. https:\/\/doi.org\/10.1245\/s10434-020-08781-3","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/xcs.0000000000000091","volume":"234","author":"ME Lundy","year":"2022","unstructured":"Lundy, M. E., et al. (2022). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal cancer with peritoneal dissemination: 30 years of experience at a single institution. Journal of the American College of Surgeons, 234, 546\u2013556. https:\/\/doi.org\/10.1097\/xcs.0000000000000091","journal-title":"Journal of the American College of Surgeons"},{"key":"10335_CR75","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jss.2018.09.032","volume":"234","author":"F Gani","year":"2019","unstructured":"Gani, F., Conca-Cheng, A. M., Nettles, B., Ahuja, N., & Johnston, F. M. (2019). Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Journal of Surgical Research, 234, 240\u2013248. https:\/\/doi.org\/10.1016\/j.jss.2018.09.032","journal-title":"Journal of Surgical Research"},{"key":"10335_CR76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1245\/s10434-018-6992-6","volume":"26","author":"P Piso","year":"2019","unstructured":"Piso, P., et al. (2019). Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Data from the DGAV StuDoQ registry with 2149 consecutive patients. Annals of Surgical Oncology, 26, 148\u2013154. https:\/\/doi.org\/10.1245\/s10434-018-6992-6","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/SLA.0b013e3181b5ae43","volume":"251","author":"TC Chua","year":"2010","unstructured":"Chua, T. C., et al. (2010). Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: Towards a new perspective of this treatment. Annals of Surgery, 251, 101\u2013106. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b5ae43","journal-title":"Annals of Surgery"},{"key":"10335_CR78","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/02656736.2017.1367846","volume":"34","author":"M Alyami","year":"2018","unstructured":"Alyami, M., et al. (2018). Ninety-day post-operative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. International Journal of Hyperthermia, 34, 532\u2013537. https:\/\/doi.org\/10.1080\/02656736.2017.1367846","journal-title":"International Journal of Hyperthermia"},{"key":"10335_CR79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1245\/s10434-015-4699-5","volume":"23","author":"GA Simkens","year":"2016","unstructured":"Simkens, G. A., et al. (2016). Treatment-related mortality after cytoreductive surgery and HIPEC in patients with colorectal peritoneal Carcinomatosis is underestimated by conventional parameters. Annals of Surgical Oncology, 23, 99\u2013105. https:\/\/doi.org\/10.1245\/s10434-015-4699-5","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1525-1438.2007.01102.x","volume":"18","author":"M Markman","year":"2008","unstructured":"Markman, M. (2008). Strategies to examine new compounds for intraperitoneal use in ovarian cancer. International Journal of Gynecological Cancer, 18, 33\u201335. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.01102.x","journal-title":"International Journal of Gynecological Cancer"},{"key":"10335_CR81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","volume":"7","author":"WP Ceelen","year":"2010","unstructured":"Ceelen, W. P., & Flessner, M. F. (2010). Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nature Reviews Clinical Oncology, 7, 108\u2013115. https:\/\/doi.org\/10.1038\/nrclinonc.2009.217","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10335_CR82","doi-asserted-by":"publisher","unstructured":"Christou, N. et al. (2021) Intraperitoneal chemotherapy for peritoneal metastases: Technical innovations, preclinical and clinical advances and future perspectives. Biology (Basel) 10. https:\/\/doi.org\/10.3390\/biology10030225","DOI":"10.3390\/biology10030225"},{"key":"10335_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3978\/j.issn.2078-6891.2015.111","volume":"7","author":"MD Goodman","year":"2016","unstructured":"Goodman, M. D., McPartland, S., Detelich, D., & Saif, M. W. (2016). Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol, 7, 45\u201357. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.111","journal-title":"J Gastrointest Oncol"},{"key":"10335_CR84","doi-asserted-by":"publisher","first-page":"e2100239","DOI":"10.1200\/po.21.00239","volume":"6","author":"TH Dellinger","year":"2022","unstructured":"Dellinger, T. H., et al. (2022). Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer. JCO Precision Oncology, 6, e2100239. https:\/\/doi.org\/10.1200\/po.21.00239","journal-title":"JCO Precision Oncology"},{"issue":"17","key":"10335_CR85","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.3390\/ijms231710078","volume":"23","author":"PQ Lim","year":"2022","unstructured":"Lim, P. Q., Han, I. H., Seow, K. M., & Chen, K. H. (2022). Hyperthermic intraperitoneal chemotherapy (HIPEC): An overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers. International Journal of Molecular Sciences, 23(17), 10078. https:\/\/doi.org\/10.3390\/ijms231710078","journal-title":"International Journal of Molecular Sciences"},{"key":"10335_CR86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s13193-016-0499-z","volume":"7","author":"A Bhatt","year":"2016","unstructured":"Bhatt, A., & Go\u00e9r\u00e9, D. (2016). Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal cancer. Indian Journal of Surgical Oncology, 7, 177\u2013187. https:\/\/doi.org\/10.1007\/s13193-016-0499-z","journal-title":"Indian Journal of Surgical Oncology"},{"key":"10335_CR87","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3748\/wjg.v18.i7.646","volume":"18","author":"XL Zhang","year":"2012","unstructured":"Zhang, X. L., Hu, A. B., Cui, S. Z., & Wei, H. B. (2012). Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells. World Journal of Gastroenterology, 18, 646\u2013653. https:\/\/doi.org\/10.3748\/wjg.v18.i7.646","journal-title":"World Journal of Gastroenterology"},{"key":"10335_CR88","first-page":"1096","volume":"41","author":"BA Teicher","year":"1981","unstructured":"Teicher, B. A., Kowal, C. D., Kennedy, K. A., & Sartorelli, A. C. (1981). Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Research, 41, 1096\u20131099.","journal-title":"Cancer Research"},{"key":"10335_CR89","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.eururo.2004.06.009","volume":"46","author":"AG van der Heijden","year":"2004","unstructured":"van der Heijden, A. G., et al. (2004). The effect of hyperthermia on Mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. European Urology, 46, 670\u2013674. https:\/\/doi.org\/10.1016\/j.eururo.2004.06.009","journal-title":"European Urology"},{"key":"10335_CR90","doi-asserted-by":"publisher","first-page":"107020","DOI":"10.1016\/j.ejso.2023.107020","volume":"49","author":"J Nogueiro","year":"2023","unstructured":"Nogueiro, J., et al. (2023). Risk factors for gastrointestinal perforation and anastomotic leak in patients submitted to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 49, 107020. https:\/\/doi.org\/10.1016\/j.ejso.2023.107020","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR91","doi-asserted-by":"publisher","first-page":"e15277","DOI":"10.7717\/peerj.15277","volume":"11","author":"J Hu","year":"2023","unstructured":"Hu, J., Wang, Z., Wang, X., & Xie, S. (2023). Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers. PeerJ, 11, e15277. https:\/\/doi.org\/10.7717\/peerj.15277","journal-title":"PeerJ"},{"key":"10335_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","volume":"7","author":"SS Mehta","year":"2016","unstructured":"Mehta, S. S., Gelli, M., Agarwal, D., & Go\u00e9r\u00e9, D. (2016). Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian Journal of Surgical Oncology, 7, 225\u2013229. https:\/\/doi.org\/10.1007\/s13193-016-0504-6","journal-title":"Indian Journal of Surgical Oncology"},{"key":"10335_CR93","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s00423-021-02353-z","volume":"406","author":"F Rosa","year":"2021","unstructured":"Rosa, F., et al. (2021). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: Analysis of short- and long-term outcomes. Langenbeck\u2019s Archives of Surgery, 406, 2797\u20132805. https:\/\/doi.org\/10.1007\/s00423-021-02353-z","journal-title":"Langenbeck's Archives of Surgery"},{"key":"10335_CR94","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.21873\/invivo.12840","volume":"36","author":"M Acs","year":"2022","unstructured":"Acs, M., Dadras, A., Blaj, S., Leebmann, H., & Piso, P. (2022). Selection criteria for Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with special emphasis on laparoscopy as an efficient tool. In Vivo, 36, 1367\u20131374. https:\/\/doi.org\/10.21873\/invivo.12840","journal-title":"In Vivo"},{"key":"10335_CR95","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jviscsurg.2014.07.005","volume":"151","author":"N Bakrin","year":"2014","unstructured":"Bakrin, N., et al. (2014). Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Journal of Visceral Surgery, 151, 347\u2013353. https:\/\/doi.org\/10.1016\/j.jviscsurg.2014.07.005","journal-title":"Journal of Visceral Surgery"},{"key":"10335_CR96","first-page":"45","volume":"7","author":"MD Goodman","year":"2015","unstructured":"Goodman, M. D., McPartland, S., Detelich, D., & Wasif Saif, M. (2015). Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. Journal of Gastrointestinal Oncology, 7, 45\u201357.","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"10335_CR97","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1245\/s10434-021-11045-3","volume":"29","author":"M Tonello","year":"2022","unstructured":"Tonello, M., et al. (2022). Microsatellite and RAS\/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Annals of Surgical Oncology, 29, 3405\u20133417. https:\/\/doi.org\/10.1245\/s10434-021-11045-3","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR98","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ejso.2010.05.024","volume":"36","author":"A Ross","year":"2010","unstructured":"Ross, A., Sardi, A., Nieroda, C., Merriman, B., & Gushchin, V. (2010). Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. European Journal of Surgical Oncology (EJSO), 36, 772\u2013776. https:\/\/doi.org\/10.1016\/j.ejso.2010.05.024","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"key":"10335_CR99","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.soda.2021.100019","volume":"3","author":"L Bijelic","year":"2021","unstructured":"Bijelic, L., et al. (2021). Designing HIPEC regimens for colon cancer: Is the available evidence being appropriately considered? Surgery Open Digestive Advance, 3, 100019. https:\/\/doi.org\/10.1016\/j.soda.2021.100019","journal-title":"Surgery Open Digestive Advance"},{"key":"10335_CR100","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","volume":"21","author":"K Turaga","year":"2014","unstructured":"Turaga, K., et al. (2014). Consensus guidelines from the American society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Annals of Surgical Oncology, 21, 1501\u20131505. https:\/\/doi.org\/10.1245\/s10434-013-3061-z","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR101","doi-asserted-by":"publisher","first-page":"516","DOI":"10.21037\/jgo-20-494","volume":"12","author":"P Fr\u00fchling","year":"2021","unstructured":"Fr\u00fchling, P., et al. (2021). Oxaliplatin-based hyperthermic intraperitoneal chemotherapy with single drug versus multiple drug treatment for colorectal cancer with peritoneal metastases: An observational cohort study. J Gastrointest Oncol, 12, 516\u2013526. https:\/\/doi.org\/10.21037\/jgo-20-494","journal-title":"J Gastrointest Oncol"},{"key":"10335_CR102","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jso.23545","volume":"109","author":"CQ Huang","year":"2014","unstructured":"Huang, C. Q., Feng, J. P., Yang, X. J., & Li, Y. (2014). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center. Journal of Surgical Oncology, 109, 730\u2013739. https:\/\/doi.org\/10.1002\/jso.23545","journal-title":"Journal of Surgical Oncology"},{"key":"10335_CR103","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3393\/ac.2019.04.30","volume":"36","author":"SJ Roh","year":"2020","unstructured":"Roh, S. J., et al. (2020). Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy with Mitomycin C used for colorectal peritoneal Carcinomatosis. Ann Coloproctol, 36, 22\u201329. https:\/\/doi.org\/10.3393\/ac.2019.04.30","journal-title":"Ann Coloproctol"},{"key":"10335_CR104","doi-asserted-by":"publisher","unstructured":"Yue, T. et al. (2022) BCL2A1 and CCL18 are predictive biomarkers of cisplatin chemotherapy and immunotherapy in colon cancer patients. Frontiers in Cell and Developmental Biology 9 \u2013 2021. https:\/\/doi.org\/10.3389\/fcell.2021.799278","DOI":"10.3389\/fcell.2021.799278"},{"key":"10335_CR105","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1245\/s10434-025-17517-0","volume":"32","author":"JM Bader","year":"2025","unstructured":"Bader, J. M., et al. (2025). A feasibility study of mass-based response drug screening to guide personalized Hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal adenocarcinoma with peritoneal metastasis. Annals of Surgical Oncology, 32, 5784\u20135794. https:\/\/doi.org\/10.1245\/s10434-025-17517-0","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR106","doi-asserted-by":"publisher","first-page":"1920276","DOI":"10.1155\/2018\/1920276","volume":"2018","author":"A Sipok","year":"2018","unstructured":"Sipok, A., et al. (2018). Comparison of survival in patients with isolated peritoneal Carcinomatosis from colorectal cancer treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic intraperitoneal chemotherapy agent. International Journal of Surgical Oncology, 2018, 1920276. https:\/\/doi.org\/10.1155\/2018\/1920276","journal-title":"International Journal of Surgical Oncology"},{"key":"10335_CR107","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/bjc.2015.18","volume":"112","author":"R Kwakman","year":"2015","unstructured":"Kwakman, R., et al. (2015). Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: A translational approach to improve survival. British Journal of Cancer, 112, 851\u2013856. https:\/\/doi.org\/10.1038\/bjc.2015.18","journal-title":"British Journal of Cancer"},{"key":"10335_CR108","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez, A., et al. (2023). Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: A phase 3 randomized clinical trial. JAMA Surgery, 158, 683\u2013691. https:\/\/doi.org\/10.1001\/jamasurg.2023.0662","journal-title":"JAMA Surgery"},{"key":"10335_CR109","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1503\/cjs.001619","volume":"64","author":"E Benzaquen","year":"2021","unstructured":"Benzaquen, E., et al. (2021). Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: A multi-institutional comparative study. Canadian Journal of Surgery, 64, E111. https:\/\/doi.org\/10.1503\/cjs.001619","journal-title":"Canadian Journal of Surgery"},{"issue":"4","key":"10335_CR110","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","volume":"218","author":"EA Levine","year":"2014","unstructured":"Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I. (2014). Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1,000 patients. Journal of the American College of Surgeons, 218(4), 573\u2013585. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2013.12.013","journal-title":"Journal of the American College of Surgeons"},{"key":"10335_CR111","doi-asserted-by":"publisher","unstructured":"Hendrikson, J., Tan, J. W. S., & Ong, C.-A. J. (2019). Can Biomarkers Predict Chemosensitivity in CRS-HIPEC Patients? Colorectal Cancer 8, CRC13. https:\/\/doi.org\/10.2217\/crc-2019-0015","DOI":"10.2217\/crc-2019-0015"},{"key":"10335_CR112","doi-asserted-by":"publisher","first-page":"10572","DOI":"10.1038\/s41598-019-46819-z","volume":"9","author":"NB Shannon","year":"2019","unstructured":"Shannon, N. B., et al. (2019). A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis. Scientific Reports, 9, 10572. https:\/\/doi.org\/10.1038\/s41598-019-46819-z","journal-title":"Scientific Reports"},{"key":"10335_CR113","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.3390\/cancers15174352","volume":"15","author":"J Jin","year":"2023","unstructured":"Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S., & Ajani, J. A. (2023). Challenges and prospects of patient-derived xenografts for cancer research. Cancers, 15, 4352.","journal-title":"Cancers"},{"key":"10335_CR114","unstructured":"Menon G, R. S. V. (2025). Peritoneal Surface Malignancies. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541114\/"},{"key":"10335_CR115","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/jco.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal, V. J., et al. (2003). Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical Oncology, 21, 3737\u20133743. https:\/\/doi.org\/10.1200\/jco.2003.04.187","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10335_CR116","doi-asserted-by":"publisher","first-page":"zraa075","DOI":"10.1093\/bjsopen\/zraa075","volume":"5","author":"A Prabhu","year":"2021","unstructured":"Prabhu, A., Brandl, A., Wakama, S., et al. (2021). Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Proof-of-concept study. BJS Open, 5(2), zraa075. https:\/\/doi.org\/10.1093\/bjsopen\/zraa075","journal-title":"BJS Open"},{"key":"10335_CR117","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008). 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Annals of Surgical Oncology, 15, 2426\u20132432. https:\/\/doi.org\/10.1245\/s10434-008-9966-2","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR118","doi-asserted-by":"publisher","unstructured":"Tonello M. et al. (2024). Systemic chemotherapy in colorectal peritoneal metastases treated with cytoreductive surgery: Systematic review and meta-analysis. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16061182","DOI":"10.3390\/cancers16061182"},{"key":"10335_CR119","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1245\/s10434-014-3647-0","volume":"21","author":"G Passot","year":"2014","unstructured":"Passot, G., et al. (2014). Pathological response to neoadjuvant chemotherapy: A new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Annals of Surgical Oncology, 21, 2608\u20132614. https:\/\/doi.org\/10.1245\/s10434-014-3647-0","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR120","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E., et al. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27, 1386\u20131422. https:\/\/doi.org\/10.1093\/annonc\/mdw235","journal-title":"Annals of Oncology"},{"key":"10335_CR121","doi-asserted-by":"publisher","unstructured":"Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 25 Suppl 3, iii1\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdu260","DOI":"10.1093\/annonc\/mdu260"},{"key":"10335_CR122","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/jco.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont, A., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 18, 2938\u20132947. https:\/\/doi.org\/10.1200\/jco.2000.18.16.2938","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR123","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard, J. Y., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 355, 1041\u20131047. https:\/\/doi.org\/10.1016\/s0140-6736(00)02034-1","journal-title":"Lancet"},{"key":"10335_CR124","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, T., et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England Journal of Medicine, 350, 2343\u20132351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"New England Journal of Medicine"},{"key":"10335_CR125","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/jco.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand, C., et al. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology, 22, 229\u2013237. https:\/\/doi.org\/10.1200\/jco.2004.05.113","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR126","doi-asserted-by":"publisher","unstructured":"Benson, A. B. et al. (2024) Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 22. https:\/\/doi.org\/10.6004\/jnccn.2024.0029","DOI":"10.6004\/jnccn.2024.0029"},{"key":"10335_CR127","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis, F., et al. (2014). Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New England Journal of Medicine, 371, 1609\u20131618. https:\/\/doi.org\/10.1056\/NEJMoa1403108","journal-title":"New England Journal of Medicine"},{"key":"10335_CR128","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini, C., et al. (2020). Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial. The lancet Oncology, 21, 497\u2013507. https:\/\/doi.org\/10.1016\/s1470-2045(19)30862-9","journal-title":"The lancet Oncology"},{"key":"10335_CR129","doi-asserted-by":"publisher","first-page":"392","DOI":"10.14740\/wjon1690","volume":"14","author":"N Areepium","year":"2023","unstructured":"Areepium, N., & Sapapsap, B. (2023). The impact of omitting 5-FU bolus from mFOLFOX6 chemotherapy regimen on hematological adverse events among patients with metastatic colorectal cancer. World J Oncol, 14, 392\u2013400. https:\/\/doi.org\/10.14740\/wjon1690","journal-title":"World J Oncol"},{"key":"10335_CR130","doi-asserted-by":"publisher","first-page":"521","DOI":"10.6004\/jnccn.2024.7029","volume":"22","author":"C Peng","year":"2024","unstructured":"Peng, C., et al. (2024). Omission of 5-fluorouracil bolus from multidrug regimens for advanced gastrointestinal cancers: A multicenter cohort study. Journal of the National Comprehensive Cancer Network, 22, 521\u2013527. https:\/\/doi.org\/10.6004\/jnccn.2024.7029","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10335_CR131","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","volume":"90","author":"E Van Cutsem","year":"2004","unstructured":"Van Cutsem, E., et al. (2004). Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer, 90, 1190\u20131197. https:\/\/doi.org\/10.1038\/sj.bjc.6601676","journal-title":"British Journal of Cancer"},{"key":"10335_CR132","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691","journal-title":"New England Journal of Medicine"},{"key":"10335_CR133","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1634\/theoncologist.2012-0003","volume":"17","author":"JH Strickler","year":"2012","unstructured":"Strickler, J. H., & Hurwitz, H. I. (2012). Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. The Oncologist, 17, 513\u2013524. https:\/\/doi.org\/10.1634\/theoncologist.2012-0003","journal-title":"The Oncologist"},{"key":"10335_CR134","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold, D., et al. (2017). Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of Oncology, 28, 1713\u20131729. https:\/\/doi.org\/10.1093\/annonc\/mdx175","journal-title":"Annals of Oncology"},{"key":"10335_CR135","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez, E., et al. (2025). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. New England Journal of Medicine, 392, 2425\u20132437. https:\/\/doi.org\/10.1056\/NEJMoa2501912","journal-title":"New England Journal of Medicine"},{"key":"10335_CR136","doi-asserted-by":"publisher","first-page":"485","DOI":"10.21037\/jgo.2017.01.07","volume":"8","author":"N Arora","year":"2017","unstructured":"Arora, N., Gupta, A., & Singh, P. P. (2017). Biological agents in gastrointestinal cancers: Adverse effects and their management. J Gastrointest Oncol, 8, 485\u2013498. https:\/\/doi.org\/10.21037\/jgo.2017.01.07","journal-title":"J Gastrointest Oncol"},{"key":"10335_CR137","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T., et al. (2020). Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. New England Journal of Medicine, 383, 2207\u20132218. https:\/\/doi.org\/10.1056\/NEJMoa2017699","journal-title":"New England Journal of Medicine"},{"key":"10335_CR138","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/jco.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz, H. J., et al. (2022). First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 Study. Journal of Clinical Oncology, 40, 161\u2013170. https:\/\/doi.org\/10.1200\/jco.21.01015","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR139","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.3390\/cancers17213496","volume":"17","author":"DA Metzger","year":"2025","unstructured":"Metzger, D. A., et al. (2025). Immunotherapy Plus Surgery Improves Survival in Microsatellite Instability-High Colon Cancer with Isolated Peritoneal Metastases. Cancers, 17, 3496.","journal-title":"Cancers"},{"key":"10335_CR140","doi-asserted-by":"publisher","unstructured":"Ornella, M. S. C. et al. (2023). Immunotherapy for peritoneal carcinomatosis: Challenges and prospective outcomes. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15082383","DOI":"10.3390\/cancers15082383"},{"key":"10335_CR141","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A., et al. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381, 303\u2013312. https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x","journal-title":"Lancet"},{"key":"10335_CR142","doi-asserted-by":"publisher","unstructured":"Yoshino, T. et al. (2014). Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs. Placebo, with best supportive care (BSC), in patients (PTS) with metastatic colorectal cancer (MCRC) refractory to standard therapies (RECOURSE). Annals of Oncology 25, ii114, https:\/\/doi.org\/10.1093\/annonc\/mdu193.22","DOI":"10.1093\/annonc\/mdu193.22"},{"key":"10335_CR143","doi-asserted-by":"publisher","unstructured":"Lee, S. J. et al. (2021) STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. Journal for Immunotherapy of Cancer 9. https:\/\/doi.org\/10.1136\/jitc-2020-002195","DOI":"10.1136\/jitc-2020-002195"},{"key":"10335_CR144","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C., et al. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences U S A, 110, 20212\u201320217. https:\/\/doi.org\/10.1073\/pnas.1320318110","journal-title":"Proceedings of the National Academy of Sciences U S A"},{"key":"10335_CR145","doi-asserted-by":"publisher","first-page":"78208","DOI":"10.18632\/oncotarget.20596","volume":"8","author":"M Nowacki","year":"2017","unstructured":"Nowacki, M., et al. (2017). Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. Oncotarget, 8, 78208\u201378224. https:\/\/doi.org\/10.18632\/oncotarget.20596","journal-title":"Oncotarget"},{"key":"10335_CR146","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R., et al. (2025). Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals. Journal of Hematology & Oncology, 18, 51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3","journal-title":"Journal of Hematology & Oncology"},{"key":"10335_CR147","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/organoids4010002","volume":"4","author":"H Kaur","year":"2025","unstructured":"Kaur, H., Wright, J. A., Worthley, D. L., Murphy, E., & Woods, S. L. (2025). Precision medicine for peritoneal carcinomatosis\u2014current advances in organoid drug testing and clinical applicability. Organoids, 4, 2.","journal-title":"Organoids"},{"key":"10335_CR148","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.21037\/jgo-20-257","volume":"12","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink, R. J., et al. (2021). Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review. Journal of Gastrointestinal Oncology, 12, S242-s258. https:\/\/doi.org\/10.21037\/jgo-20-257","journal-title":"Journal of Gastrointestinal Oncology"},{"issue":"11","key":"10335_CR149","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3390\/jcm13113320","volume":"13","author":"F Ramalho-Vasconcelos","year":"2024","unstructured":"Ramalho-Vasconcelos, F., et al. (2024). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of gastric cancer: Feasibility, efficacy and safety-a systematic review and meta-analysis. Journal of Clinical Medicine, 13(11), 3320. https:\/\/doi.org\/10.3390\/jcm13113320","journal-title":"Journal of Clinical Medicine"},{"key":"10335_CR150","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0300891619868013","volume":"106","author":"I Gockel","year":"2020","unstructured":"Gockel, I., et al. (2020). Pressurized IntraPeritoneal Aerosol chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori, 106, 70\u201378. https:\/\/doi.org\/10.1177\/0300891619868013","journal-title":"Tumori"},{"key":"10335_CR151","doi-asserted-by":"publisher","unstructured":"Sleiman, M. J. et al. (2024) Pressurized intraperitoneal aerosol chemotherapy for peritoneal Carcinomatosis in colorectal cancer patients: A systematic review of the evidence. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16213661","DOI":"10.3390\/cancers16213661"},{"key":"10335_CR152","doi-asserted-by":"publisher","unstructured":"De Simone, M. et al. (2020). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with Oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal Carcinomatosis: An open-label, single-arm, phase II clinical trial. Biomedicines 8. https:\/\/doi.org\/10.3390\/biomedicines8050102","DOI":"10.3390\/biomedicines8050102"},{"issue":"9","key":"10335_CR153","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.ejso.2024.108487","volume":"50","author":"P Rauwerdink","year":"2024","unstructured":"Rauwerdink, P., et al. (2024). First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II). European Journal of Surgical Oncology, 50(9), 108487. https:\/\/doi.org\/10.1016\/j.ejso.2024.108487","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR154","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/dcr.0000000000002323","volume":"65","author":"JD Vogel","year":"2022","unstructured":"Vogel, J. D., et al. (2022). The American society of colon and rectal surgeons clinical practice guidelines for the management of colon cancer. Diseases of the Colon and Rectum, 65, 148\u2013177. https:\/\/doi.org\/10.1097\/dcr.0000000000002323","journal-title":"Diseases of the Colon and Rectum"},{"key":"10335_CR155","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/jco.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K., et al. (2023). Treatment of metastatic colorectal cancer: ASCO guideline. Journal of Clinical Oncology, 41, 678\u2013700. https:\/\/doi.org\/10.1200\/jco.22.01690","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR156","unstructured":"(2025) NCCN Guidelines Version 2.2025 Rectal Carcinoma, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed\u00a012\/1\/2025."},{"key":"10335_CR157","doi-asserted-by":"publisher","first-page":"e35869","DOI":"10.1002\/cncr.35869","volume":"131","author":"KS Schultz","year":"2025","unstructured":"Schultz, K. S., et al. (2025). Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer, 131, e35869. https:\/\/doi.org\/10.1002\/cncr.35869","journal-title":"Cancer"},{"key":"10335_CR158","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/jco.22.02644","volume":"42","author":"ES Zwanenburg","year":"2024","unstructured":"Zwanenburg, E. S., et al. (2024). Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): 5-year results of a randomized multicenter trial. Journal of Clinical Oncology, 42, 140\u2013145. https:\/\/doi.org\/10.1200\/jco.22.02644","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR159","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9, D., et al. (2020). Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study. The Lancet Oncology, 21, 1147\u20131154. https:\/\/doi.org\/10.1016\/s1470-2045(20)30322-3","journal-title":"The Lancet Oncology"},{"key":"10335_CR160","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin, P. H., et al. (2016). Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. European Journal of Cancer, 53, 155\u2013162. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.017","journal-title":"European Journal of Cancer"},{"key":"10335_CR161","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12885-018-4096-0","volume":"18","author":"A Arjona-S\u00e1nchez","year":"2018","unstructured":"Arjona-S\u00e1nchez, A., et al. (2018). HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer, 18, 183. https:\/\/doi.org\/10.1186\/s12885-018-4096-0","journal-title":"BMC Cancer"},{"key":"10335_CR162","doi-asserted-by":"publisher","unstructured":"Sommariva, A. et al. (2022). Colorectal cancer with peritoneal metastases: The impact of the results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 trials on peritoneal disease management. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15010165","DOI":"10.3390\/cancers15010165"},{"key":"10335_CR163","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1245\/s10434-025-17650-w","volume":"32","author":"MM Wach","year":"2025","unstructured":"Wach, M. M., & Dineen, S. P. (2025). ASO practice guideline series: Management of colorectal peritoneal metastases. Annals of Surgical Oncology, 32, 6589\u20136603. https:\/\/doi.org\/10.1245\/s10434-025-17650-w","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR164","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM van Stein","year":"2021","unstructured":"van Stein, R. M., Aalbers, A. G. J., Sonke, G. S., & van Driel, W. J. (2021). Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: A review. JAMA Oncology, 7, 1231\u20131238. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580","journal-title":"JAMA Oncology"},{"key":"10335_CR165","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/dcr.0000000000001156","volume":"61","author":"D Baratti","year":"2018","unstructured":"Baratti, D., et al. (2018). Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Diseases of the Colon and Rectum, 61, 1026\u20131034. https:\/\/doi.org\/10.1097\/dcr.0000000000001156","journal-title":"Diseases of the Colon and Rectum"},{"key":"10335_CR166","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1245\/s10434-023-13279-9","volume":"30","author":"F Schell","year":"2023","unstructured":"Schell, F., et al. (2023). Influence of extraperitoneal metastases on the curative-intent management of colorectal peritoneal metastases. Annals of Surgical Oncology, 30, 4444\u20134454. https:\/\/doi.org\/10.1245\/s10434-023-13279-9","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR167","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1245\/s10434-021-10925-y","volume":"29","author":"MCE Polderdijk","year":"2022","unstructured":"Polderdijk, M. C. E., et al. (2022). Outcomes of combined peritoneal and local treatment for patients with peritoneal and limited liver metastases of colorectal origin: A systematic review and meta-analysis. Annals of Surgical Oncology, 29, 1952\u20131962. https:\/\/doi.org\/10.1245\/s10434-021-10925-y","journal-title":"Annals of Surgical Oncology"},{"key":"10335_CR168","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P., & Sugarbaker, P. H. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treatment and Research, 82, 359\u2013374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23","journal-title":"Cancer Treatment and Research"},{"key":"10335_CR169","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/jco.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias, D., et al. (2010). Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. Journal of Clinical Oncology, 28, 63\u201368. https:\/\/doi.org\/10.1200\/jco.2009.23.9285","journal-title":"Journal of Clinical Oncology"},{"key":"10335_CR170","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","volume":"203","author":"RG da Silva","year":"2006","unstructured":"da Silva, R. G., & Sugarbaker, P. H. (2006). Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Journal of the American College of Surgeons, 203, 878\u2013886. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.08.024","journal-title":"Journal of the American College of Surgeons"},{"issue":"1","key":"10335_CR171","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejso.2020.07.038","volume":"47","author":"R Lo Dico","year":"2021","unstructured":"Lo Dico, R., Faron, M., Yonemura, Y., et al. (2021). Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 47(1), 89\u2013100. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.038","journal-title":"European Journal of Surgical Oncology"},{"key":"10335_CR172","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers, K. P., et al. (2019). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: Protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 19, 390. https:\/\/doi.org\/10.1186\/s12885-019-5545-0","journal-title":"BMC Cancer"},{"key":"10335_CR173","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamasurg.2021.1642","volume":"156","author":"KP Rovers","year":"2021","unstructured":"Rovers, K. P., et al. (2021). Perioperative systemic therapy vs Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 randomized clinical trial. JAMA Surgery, 156, 710\u2013720. https:\/\/doi.org\/10.1001\/jamasurg.2021.1642","journal-title":"JAMA Surgery"},{"key":"10335_CR174","unstructured":"(2025) Perioperative Systemic Therapy and Cytoreductive Surgery with HIPEC Versus Upfront Cytoreductive Surgery with HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study. \nhttps:\/\/clinicaltrials.gov\/study\/NCT02758951. Accessed\u00a012\/1\/2025."},{"key":"10335_CR175","unstructured":"(2025) A Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy After Colectomy in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis. \nhttps:\/\/clinicaltrials.gov\/study\/NCT04370925. Accessed\u00a012\/1\/2025."},{"key":"10335_CR176","unstructured":"(2025) Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. \nhttps:\/\/clinicaltrials.gov\/study\/NCT03914820. Accessed\u00a012\/1\/2025."},{"key":"10335_CR177","doi-asserted-by":"publisher","first-page":"e051324","DOI":"10.1136\/bmjopen-2021-051324","volume":"12","author":"F Pacelli","year":"2022","unstructured":"Pacelli, F., et al. (2022). Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: Short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial. British Medical Journal Open, 12, e051324. https:\/\/doi.org\/10.1136\/bmjopen-2021-051324","journal-title":"British Medical Journal Open"},{"key":"10335_CR178","unstructured":"(2025) Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Mytomicin-C After Complete Surgical Cytoreduction in Patients with Colon Cancer Peritoneal Metastases. \nhttps:\/\/clinicaltrials.gov\/study\/NCT05250648. Accessed\u00a012\/1\/2025."},{"key":"10335_CR179","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","volume":"22","author":"F Pereira","year":"2022","unstructured":"Pereira, F., et al. (2022). GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer, 22, 536. https:\/\/doi.org\/10.1186\/s12885-022-09572-7","journal-title":"BMC Cancer"},{"key":"10335_CR180","unstructured":"(2025) EFFIPEC - Efficacy of Hyperthermic Intraperitoneal Chemotherapy, Single-arm Phase I Study, Followed by an Open-label, Randomized, Controlled Registry-based Phase III Trial. \nhttps:\/\/clinicaltrials.gov\/study\/NCT04861558. Accessed\u00a012\/1\/2025."},{"key":"10335_CR181","doi-asserted-by":"publisher","first-page":"e0294018","DOI":"10.1371\/journal.pone.0294018","volume":"19","author":"L Ghanipour","year":"2024","unstructured":"Ghanipour, L., et al. (2024). Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PLoS ONE, 19, e0294018. https:\/\/doi.org\/10.1371\/journal.pone.0294018","journal-title":"PLoS ONE"},{"key":"10335_CR182","unstructured":"(2025) Proactive Management of Endoperitoneal Spread in Colonic Cancer. \nhttps:\/\/clinicaltrials.gov\/study\/NCT02974556. Accessed\u00a012\/1\/2025."},{"issue":"13","key":"10335_CR183","doi-asserted-by":"publisher","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","volume":"30","author":"A Bhatt","year":"2023","unstructured":"Bhatt, A., Glehen, O., Zivanovic, O., et al. (2023). The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: Epithelial ovarian cancer. Annals of Surgical Oncology, 30(13), 8115\u20138137. https:\/\/doi.org\/10.1245\/s10434-023-13932-3","journal-title":"Annals of Surgical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10335-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:59:57Z","timestamp":1776916797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10335-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":183,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10335"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10335-0","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tools were used for grammar and clarity in the writing process. All substantive content including study design, analysis, and writing decisions were made solely by the authors. The authors wrote the manuscript, verified all content, and are responsible for the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI-assisted technologies"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}